Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Protective Role of BST2 Polymorphisms in Mother-to-Child Transmission of HIV-1 and Adult AIDS Progression.

Authors: Kamada, Anselmo J  Bianco, Anna M  Zupin, Luisa  Girardelli, Martina  Matte, Maria C C  Medeiros, Rúbia Marília de  Almeida, Sabrina Esteves de Matos  Rocha, Marineide M  Segat, Ludovica  Chies, José A B  Kuhn, Louise  Crovella, Sergio 
Citation: Kamada AJ, etal., J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):237-41. doi: 10.1097/QAI.0000000000000949.
Pubmed: (View Article at PubMed) PMID:26885809
DOI: Full-text: DOI:10.1097/QAI.0000000000000949

Bone marrow stromal cell antigen-2 (BST-2)/Tetherin is a restriction factor that prevents Human immunodeficiency virus type 1 (HIV-1) release from infected cells and mediates pro-inflammatory cytokine production. This study investigated the risk conferred by single nucleotide polymorphisms (rs919266, rs9192677, and rs9576) at BST-2 coding gene (BST2) in HIV-1 mother-to-child transmission and in disease progression. Initially, 101 HIV-1+ pregnant women and 331 neonates exposed to HIV-1 from Zambia were enrolled. Additional BST2 single nucleotide polymorphism analyses were performed in 2 cohorts with acquired immunodeficiency syndrome (AIDS) progression: an adult Brazilian cohort (37 rapid, 30 chronic and 21 long-term non-progressors) and an Italian pediatric cohort (21 rapid and 67 slow progressors). The rs9576A allele was nominally associated with protection during breastfeeding (P = 0.019) and individuals carrying rs919266 GA showed slower progression to AIDS (P = 0.033). Despite the influence of rs919266 and rs9576 on BST2 expression being still undetermined, a preventive role by BST2 polymorphisms was found during HIV-1 infection.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 14398494
Created: 2019-04-23
Species: All species
Last Modified: 2019-04-23
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.